CM
PTCT icon

Crestline Management’s PTC Therapeutics PTCT Stock Holding History

Crestline Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-37,203
Closed -$1.25M – 216
2018
Q2 		$1.25M Sell
37,203
-40,426
-52% -$1.26M 0.13% 181
2018
Q1 		$2.1M Buy
77,629
+34,509
+80% +$874K 0.26% 56
2017
Q4 		$719K Sell
43,120
-4,598
-10% -$77.8K 0.07% 128
2017
Q3 		$955K Sell
47,718
-50,071
-51% -$980K 0.13% 102
2017
Q2 		$1.79M Buy
+97,789
New +$1.32M 0.24% 47

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Crestline Management's PTCT Position: Q3 2018 in Review

Crestline Management sold out of PTC Therapeutics (PTCT) in Q3 2018, closing a stake of 37,203 shares — an estimated $1.25M sold.

Crestline Management first reported a position in PTCT in Q2 2017 and held it in 5 quarters. The position peaked at $2.1M in Q1 2018. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2018.

  • Crestline Management reported no remaining PTC Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Crestline Management sold 37,203 PTC Therapeutics shares in Q3 2018, an estimated $1.25M.
  • Crestline Management first reported a position in PTC Therapeutics in Q2 2017 and held it in 5 quarters.
  • Crestline Management's PTC Therapeutics position peaked at $2.1M in Q1 2018.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.